Natalizumab induced blood eosinophilia: A retrospective pharmacovigilance cohort study and review of the literature.

Diem, L; Hoepner, R; Bagnoud, M; Salmen, A; Chan, A; Friedli, C

Diem, L; Hoepner, R; Bagnoud, M; Salmen, A; Chan, A; Friedli, C.

Afiliação

Diem L; Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Hoepner R; Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Bagnoud M; Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland; Graduate School for Cellular and Biomedical Sciences, University of Bern, Bern, Switzerland.
Salmen A; Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Chan A; Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Friedli C; Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. Electronic address: christoph.friedli@insel.ch.

J Neuroimmunol ; 353: 577505, 2021 04 15.

Article em En | MEDLINE | ID: mdl-33548621

Assuntos

Eosinofilia/induzido quimicamente; Fatores Imunológicos/efeitos adversos; Esclerose Múltipla Recidivante-Remitente/tratamento farmacológico; Natalizumab/efeitos adversos; Farmacovigilância; Adulto; Feminino; Humanos; Masculino; Pessoa de Meia-Idade; Estudos Retrospectivos

Palavras-chave

Immunotherapy; Multiple sclerosis; Natalizumab; Pulmonary eosinophilia; Side effects

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Esclerose Múltipla Recidivante-Remitente / Eosinofilia / Farmacovigilância / Natalizumab / Fatores Imunológicos Idioma: En Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Suíça

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google